Teva And Celltrion Gain Arthritis Advantage On Rituximab
Truxima Biosimilar Now Available In Rheumatoid Arthritis Indication In US
Executive Summary
Teva and Celltrion’s Truxima rituximab biosimilar is now available with a rheumatoid arthritis indication in the US, the firms have revealed, giving it a potential advantage over Pfizer’s Ruxience version.
You may also be interested in...
Building A US Business: Celltrion’s New CCO Talks Strategy
With Celltrion transitioning to a direct sales model in the US after previously partnering with other firms to market its biosimilars, the company’s new US chief commercial officer, Tom Nusbickel, talks about how the firm is gearing up to launch three key products.
Building A US Business: Celltrion’s New CCO Talks Strategy
With Celltrion transitioning to a direct sales model in the US after previously partnering with other firms to market its biosimilars, the company’s new US chief commercial officer, Tom Nusbickel, talks to Generics Bulletin about how the firm is gearing up to launch three key products.
Amgen Rivals Teva With Rituximab Approved For RA
Amgen has added a further treatment for inflammatory diseases to its vast portfolio, with the FDA approving its rituximab biosimilar Riabni for rheumatoid arthritis.